Woodcock Era At CDER Ends: Cavazzoni Becomes Permanent Director Of US FDA’s Drug Center
Patrizia Cavazzoni, who likely represents a somewhat different leadership style for CDER, distinguished herself while leading the center temporarily during the COVID-19 pandemic.
You may also be interested in...
Wall Street is worried that a cluster of recent negative regulatory events means tougher reviews going forward. That concern is probably overdone, but a year into the COVID pandemic is a good time to take stock of how FDA is doing.
First quarter earnings preview: US drug pricing reform, an uncertain regulatory outlook and new focus on M&A are rising challenges that could put the industry's growth at risk.
Dunn’s participation at the panel meeting ended speculation that he left the US FDA.